Swk Holdings's Corporate Customers have recorded a surge in their cost of revenue by 129.05 % in the 4 quarter 2025 year on year, sequentially costs of revenue grew by 305.07 %. During the corresponding time, Swk Holdings Corporation saw a revenue deteriorated by -22.74 % year on year, sequentially revenue fell by -20.13 %. While revenue at the Swk Holdings Corporation's corporate clients recorded rose by 24.7 % year on year, sequentially revenue grew by 4.79 %.
Swk Holdings's Customers have recorded a surge in their cost of revenue by 129.05 % in the 4 quarter 2025 year on year, sequentially costs of revenue grew by 305.07 %, for the same period Swk Holdings Corporation revnue deteriorated by -22.74 % year on year, sequentially revenue fell by -20.13 %.
Swk Holdings's Comment on Sales, Marketing and Customers
Until the third quarter of 2025, the company provided pharmaceutical development, formulation, and manufacturing services. In that quarter, it sold substantially all assets of its Pharmaceutical Development segment. Following the sale, the company's operations are focused exclusively on the Finance Receivables segment. Customers in this segment include outside investors and investment management clients with interests in healthcare-related companies. The company competes with non-bank financial institutions, federal or state-chartered banks, venture debt funds, venture capital funds, private equity funds, pharmaceutical royalty and other investment funds, business development companies, and investment banks. Competition in the Finance Receivables segment is less intense for transactions under $50.0 million. Previously, competition in the Pharmaceutical Development segment included large multinational contract development and manufacturing organizations (CDMOs), smaller specialized CDMOs, and the in-house capabilities of pharmaceutical and biotech companies.
Swk Holdings’s Comment on Sales, Marketing and Customers
Until the third quarter of 2025, the company provided pharmaceutical development, formulation, and manufacturing services. In that quarter, it sold substantially all assets of its Pharmaceutical Development segment. Following the sale, the company's operations are focused exclusively on the Finance Receivables segment. Customers in this segment include outside investors and investment management clients with interests in healthcare-related companies. The company competes with non-bank financial institutions, federal or state-chartered banks, venture debt funds, venture capital funds, private equity funds, pharmaceutical royalty and other investment funds, business development companies, and investment banks. Competition in the Finance Receivables segment is less intense for transactions under $50.0 million. Previously, competition in the Pharmaceutical Development segment included large multinational contract development and manufacturing organizations (CDMOs), smaller specialized CDMOs, and the in-house capabilities of pharmaceutical and biotech companies.
Sources:
Swk Holdings Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Swk Holdings Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Swk Holdings Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
-30.33 %
4.46 %